Who owns innovation when AI takes the reins? Fenwick’s Antonia Sequeira and Fredrick Tsang dive into the game-changing Thaler v. Vidal decision and what it means for the future of life sciences and technology patents.
- AI is shaking up drug discovery, cutting timelines by 30%, and enabling breakthroughs in genomic analysis.
- Only humans can be inventors on patents. But it leaves open a big question: what happens when AI and humans team up on an idea?
- AI alone doesn’t qualify as an inventor—human involvement is essential.
Their advice? Bring legal counsel into the fold early to keep your IP strategy sharp in this evolving frontier.
